News

Daily Pill Shows Promise in Slowing Type 1 Diabetes

4 hours ago
Less than a minute


A 2-year follow-up of the randomized, placebo-controlled BANDIT trial shows that stopping baricitinib leads to a loss of therapeutic benefit, supporting its evaluation in earlier stages of type 1 diabetes to determine whether it can prevent or delay clinical onset. In 2023, researchers in Australia launched the pioneering BANDIT (Baricitinib in New Onset Type 1 […]

Source link

Related posts:

  1. New quintuple agonist shows promise for treating obesity and type 2 diabetes
  2. Mitochondrial protein misfolding found to kill pancreatic cells in type 2 diabetes
  3. Sugar layer on beta cells prevents immune system from causing type 1 diabetes
  4. New antibody cocktail shows promise for treating multiple strains of flu
See also  Judge rules against Republican-controlled body over Utah district map
Tags
4 hours ago
Less than a minute
Back to top button
close